Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Labeling updates underscore the importance of using compatible autoinjectors with specific glatiramer acetate injection products to prevent medication errors.

Cross-Compatibility Issues With Autoinjectors Highlighted in New FDA Labeling Update of Glatiramer Acetate Injection

The study found that Black, Asian, and Hispanic individuals have 7- to 4-fold higher incidence of anti-NMDAR encephalitis, a rare epileptic condition, than White individuals.

Anti-NMDA Receptor Encephalitis Disproportionately Impacts Black, Hispanic, and Asian Populations, Study Shows

Solid Biosciences is expecting to provide initial safety data on SGT-003 from the first couple of pediatric patients with Duchenne muscular dystrophy enrolled in the phase 1/2 INSPIRE Duchenne trial in mid-2024.

FDA Grants Rare Pediatric Disease Designation to DMD Gene Therapy Candidate SGT-003

Videos

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD

, has been with the team since October 2019. Follow him on Twitter 

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

Building the Archetype for MOGAD Care: Introducing Mayo’s New Clinic

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

CMSC 2024: What to Expect From This Year's Annual Meeting

Cure SMA introduces tools aiding in SMA clinical trial navigation and participation empowerment.

Cure SMA Unveils Initiatives to Improve Clinical Trial Accessibility

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Rapid Readout: Clinical Updates in Multiple Sclerosis From CMSC 2020

Consortium of Multiple Sclerosis Centers Annual Meeting

The Multidisciplinary Theme of CMSC 2020

Progressive MS: The 2020 Whitaker Lecture

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Post Hoc Analysis: Phase 3 ASCLEPIOS I and II Trials in Relapsing MS

Primary Results From the ENSEMBLE PLUS Study

Post Hoc Analysis: Phase 3 EXPAND Trial in Secondary Progressive MS

Open-Label Extension: Phase 3 OPERA I and II Trials in Relapsing MS

CMSC Data Release: Abstract DXT58 and MS Risk Reduction

Open-Label Extension: BTKI in Relapsing MS Over 108 Weeks

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

The News Network video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases.